Status: Not yet recruiting
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).
Participants needed: 250
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Eidos Therapeutics, a BridgeBio companyUpdated: Aug 11, 2025
Eligibility criteria
Participants who completed the AG10-501 study with a diagnosis of ATTR-PN only,... [+7]